Economic evaluation of drug abuse treatment and HIV prevention programs in pregnant women: A systematic review

Addictive Behaviors

Volumn 37, Issue 1, 2012, Pages 1-10

  Ruger, Jennifer Prah ^a   Lazar, Christina M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug abuse treatment; Economic evaluation; HIV prevention; Pregnant women; Prevention of mother to child transmission (PMTCT); Systematic review

Indexed keywords

METHADONE; NEVIRAPINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; CHECKLIST; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DETOXIFICATION; DISEASE TRANSMISSION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; METHADONE TREATMENT; PREGNANT WOMAN; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

CHECKLIST; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PUBLIC HEALTH; SUBSTANCE-RELATED DISORDERS;

EID: 80054734417     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2011.07.042     Document Type: Review

References (81)

1. Asch D.A., Jepson C., Hershey J.C., Baron J., Ubel P.A. When money is saved by reducing healthcare costs, where do U.S. primary care physicians think the money goes?. The American Journal of Managed Care 2003, 9:438-442.
2. Banta H.D., de Wit G.A. Public health services and cost-effectiveness analysis. Annual Review of Public Health 2008, 29:383-397.
3. Bard K.A., Coles C.D., Platzman K.A., Lynch M.E. The effects of prenatal drug exposure, term status, and caregiving on arousal and arousal modulation of 8-week-old infants. Developmental Psychobiology 2000, 36:194-212.
4. Barnett P.G., Hui S.S. The cost-effectiveness of methadone maintenance. The Mount Sinai Journal of Medicine 2000, 67(5-6):365-374.
5. Boyer C.B., Barrett D.C., Peterman T.A., Bolan G. Sexually transmitted disease (STD) and HIV risk in heterosexual adults attending a public STD clinic: Evaluation of a randomized controlled behavioral risk-reduction intervention trial. AIDS 1997, 11(3):359-367.
6. Brauer C.A., Neumann P.J., Rosen A.B. Trends in cost effectiveness analyses in orthopaedic surgery. Clinical Orthopaedics and Related Research 2007, 457:42-48.
7. Brauer C.A., Rosen A.B., Greenberg D., Neumann P.J. Trends in the measurement of health utilities in published cost-utility analyses. Value in Health 2006, 9:213-218.
8. Brocklehurst P., French R. The association between maternal HIV infection and perinatal outcome: A systematic review of the literature and meta-analysis. British Journal of Obstetrics and Gynaecology 1998, 105(8):836-848.
9. Carande-Kulis V.G., Maciosek M.V., Briss P.A., Teutsch S.M., Zaza S., Truman B.I., et al. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. American Journal of Preventive Medicine 2000, 18(1 Suppl.):75-91.
10. CDC HIV/AIDS among Women. August Available. http://img.thebody.com/cdc/pdfs/women_hiv.pdf.
11. Chirgwin K.D., Feldman J., Dehovitz J.A., Minkoff H., Landesman S.H. Incidence and risk factors for heterosexually acquired HIV in an inner-city cohort of women: Temporal association with pregnancy. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1999, 20(3):295-299.
12. Cohen J.T., Neumann P.J., Weinstein M.C. Does preventive care save money? Health economics and the presidential candidates. The New England Journal of Medicine 2008, 358:661-663.
13. Daley M., Argeriou M., McCarty D., Callahan J.J., Shepard D.S., Williams C.N. The costs of crime and the benefits of substance abuse treatment for pregnant women. Journal of Substance Abuse Treatment 2000, 19(4):445-458.
14. Daley M., Argeriou M., McCarty D., Callahan J.J., Shepard D.S., Williams C.N. The impact of substance abuse treatment modality on birth weight and health care expenditures. Journal of Psychoactive Drugs 2001, 33(1):57-66.
15. Daley M., Shepard D.S., Bury-Maynard D. Changes in quality of life for pregnant women in substance user treatment: Developing a quality of life index for the addictions. Substance Use & Misuse 2005, 40(3):375-394.
16. Dicker M., Leighton E.A. Trends in the U.S. prevalence of drug-using parturient women and drug-affected newborns, 1979 through 1990. American Journal of Public Health 1994, 84:1433-1438.
17. DiClemente R.J., Wingood G.M. A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women. JAMA 1995, 274(16):1271-1276.
18. Drummond M.F., Jefferson T.O. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996, 313:275-283.
19. Drummond M.F., O'Brien B.J., Stoddart G.L., Torrance G.W. Methods for the economic evaluation of health care programmes 1997, Oxford University Press, New York.
20. Ebrahim S.H., Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstetrics and Gynecology 2003, 101(2):374-379.
21. Frank D.A., Augustyn M., Knight W.G., Pell T., Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure. JAMA 2001, 285:1613-1625.
22. French M.T., Drummond M. A research agenda for economic evaluation of substance abuse services. Journal of Substance Abuse Treatment 2005, 29:125-137.
23. Giacomini M., Miller F., O'Brien B.J. Economic considerations for health insurance coverage of emerging genetic tests. Community Genetics 2003, 6:61-73.
24. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein (Eds.).
25. Grosse S.D., Teutsch S.M., Haddix A.C. Lessons from cost-effectiveness research for United States public health policy. Annual Review of Public Health 2007, 28:365-391.
26. Halpern M.T., Read J.S., Ganoczy D.A., Harris D.R. Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1. AIDS 2000, 14(6):691-700.
27. Harvard Center for Risk Analysis Available. http://www.hcra.harvard.edu/.
28. Hobfoll S.E., Jackson A.P., Lavin J., Britton P.J., Shepherd J.B. Reducing inner-city women's AIDS risk activities: A study of single, pregnant women. Health Psychology 1994, 13(5):397-403.
29. Jansson L.M., Svikis D., Lee J., Paluzzi P., Rutigliano P., Hackerman F. Pregnancy and addiction. A comprehensive care model. Journal of Substance Abuse Treatment 1996, 13(4):321-329.
30. Jefferson T., Demicheli V., Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA 2002, 287:2809-2812.
31. Kamb M.L., Fishbein M., Douglas J.M., Rhodes F., Rogers J., Bolan G., et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: A randomized controlled trial. Project RESPECT Study Group. JAMA 1998, 280(13):1161-1167.
32. Kelly J.J., Davis P.G., Henschke P.N. The drug epidemic: Effects on newborn infants and health resource consumption at a tertiary perinatal centre. Journal of Paediatrics and Child Health 2000, 36:262-264.
33. Kelly J.A., Murphy D.A., Washington C.D., Wilson T.S., Koob J.J., Davis D.R., et al. The effects of HIV/AIDS intervention groups for high-risk women in urban clinics. American Journal of Public Health 1994, 84(12):1918-1922.
34. Kokkevi A., Loukadakis M., Plagianakou S., Politikou K., Stefanis C. Sharp increase in illicit drug use in Greece: Trends from a general population survey on licit and illicit drug use. European Addiction Research 2000, 6:42-49.
35. Kumar R.M., Uduman S.A., Khurranna A.K. Impact of maternal HIV-1 infection on perinatal outcome. International Journal of Gynecology and Obstetrics 1995, 49(2):137-143.
36. Mansergh G., Haddix A.C., Steketee R.W., Nieburg P.I., Hu D.J., Simonds R.J., et al. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting. JAMA 1996, 276(2):139-145.
37. Marseille E., Kahn J.G., Saba J. Cost-effectiveness of antriviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 1998, 12(8):939-948.
38. Merrick J.C. Maternal substance abuse during pregnancy. Policy implications in the United States. Journal of Legal Medicine 1993, 14:57-71.
39. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Lancet 1999, 354:1896-1900.
40. Ness R.B., Grisso J.A., Hirschinger N., Markovic N., Shaw L.M., Day N.L., et al. Cocaine and tobacco use and the risk of spontaneous abortion. The New England Journal of Medicine 1999, 340:333-339.
41. Neumann P.J. Why don't Americans use cost-effectiveness analysis?. The American Journal of Managed Care 2004, 10:308-312.
42. Neumann P.J. Using cost-effectiveness analysis to improve health care 2005, Oxford University Press, New York.
43. Neumann P.J., Fang C.H., Cohen J.T. 30years of pharmaceutical cost-utility analyses: Growth, diversity, and methodological improvement. PharmacoEconomics 2009, 27(10):861-872.
44. Neumann P.J., Greenberg D., Olchanski N.V., Stone P.W., Rosen A.B. Growth and quality of the cost-utility literature, 1976-2001. Value in Health 2005, 8:3-9.
45. Neumann P.J., Stone P.W., Chapman R.H., Sandberg E.A., Bell C.M. The quality of reporting in published cost-utility analyses, 1976-1997. Annals of Internal Medicine 2000, 132:964-972.
46. NIMH The NIMH multisite HIV prevention trial: Reducing HIV sexual risk behavior. Science 1998, 280:1889-1894.
47. Ostrea E.M., Ostrea A.R., Simpson P.M. Mortality within the first two years in infants exposed to cocaine, opiate, or cannabinoid during gestation. Pediatrics 1997, 100:79-83.
48. Pinkerton S.D., Holtgrave D.R., Layde P.M. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States. Preventive Medicine 2000, 30(1):64-69.
49. Pinkerton S.D., Johnson-Masotti A.P., Otto-Salaj L.L., Stevenson L.Y., Hoffmann R.G. Cost-effectiveness of an HIV prevention intervention for mentally ill adults. Mental Health Services Research 2001, 3(1):45-55.
50. Prosser L.A., Koplan J.P., Neumann P.J., Weinstein M.C. Barriers to using cost-effectiveness analysis in managed care decision making. The American Journal of Managed Care 1999, 6:173-179.
51. Ratcliffe J., Ades A.E., Gibb D., Sculpher M.J., Briggs A.H. Prevention of mother-to-child transmission of HIV-1 infection: Alternative strategies and their cost-effectiveness. AIDS 1998, 12(11):1381-1388.
52. Rely K., Bertozzi S.M., Avila-Figueroa C., Guijarro M.T. Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting. Health Policy and Planning 2003, 18(3):290-298.
53. Remafedi G. Cognitive and behavioral adaptations to HIV/AIDS among gay and bisexual adolescents. The Journal of Adolescent Health 1994, 15(2):142-148.
54. Rennie D., Luft H.S. Pharmacoeconomic analyses: Making them transparent, making them credible. JAMA 2000, 283:2158-2160.
55. Resch S., Altice F.L., Paltiel A.D. Cost-effectiveness of HIV screening for incarcerated pregnant women. Journal of Acquired Immune Deficiency Syndromes 2005, 38(2):163-173.
56. Rozenbaum M.H., Verweel G., Folkerts D.K., Dronkers F., van den Hoek J.A., Hartwig N.G., et al. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. International Journal of STD & AIDS 2008, 19(10):668-675.
57. Ruger J.P. Health and social justice 2009, Oxford University Press, Oxford.
58. Ruger, J. P. (submitted for publication). The cost side of health morality.
59. Ruger J.P., Emmons K.M. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: A systematic review. Value in Health 2008, 11(2):180-190.
60. Russell L.B. Prevention's potential for slowing the growth of medical spending 2007, National Coalition on Health Care, Washington, DC, October. Available. http://www.ihhcpar.rutgers.edu/downloads/RussellNCHC2007.pdf.
61. Saha S., Hoerger T.J., Pignone M.P., Teutsch S.M., Helfand M., Mandelblatt J.S., et al. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. American Journal of Preventive Medicine 2001, 20(3 Suppl.):36-43.
62. SAMHSA Results from the 2002 national survey on drug use and health: National findings 2003, Office of Applied Studies, Rockville, MD, Available. http://www.oas.samhsa.gov/nhsda/2k2nsduh/results/2k2Results.htm.
63. Shain R.N., Piper J.M., Newton E.R., Perdue S.T., Ramos R., Champion J.D., et al. A randomized, controlled trial of a behavioral intervention to prevent sexually transmitted disease among minority women. The New England Journal of Medicine 1999, 340(2):93-100.
64. Sherwood R.A., Keating J., Kavvadia V., Greenough A., Peters T.J. Substance misuse in early pregnancy and relationship to fetal outcome. European Journal of Pediatrics 1999, 158:488-492.
65. Sindelar J. Social costs of alcohol. Journal of Drug Issues 1998, 28(3):763-780.
66. Sindelar J., Manning W. Cost-benefit and cost-effectiveness analyses: Issues in the evaluation of the treatment of illicit drug abuse. Treating Drug Abusers Effectively 1997, 187-222. Blackwell, Cambridge, MA. J.A. Egertson, D.M. Fox, A.I. Leshner (Eds.).
67. Sonnad S., Greenberg D., Rosen A., Neumann P. Diffusion of published cost-utility analyses in the field of health policy and practice. International Journal of Technology Assessment in Health Care 2005, 21:399-402.
68. Soorapanth S., Sansom S., Bulterys M., Besser M., Theron G., Fowler M.G. Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings. Journal of Acquired Immune Deficiency Syndromes 2006, 42(2):213-221.
69. St.Lawrence J.S., Brasfield T.L., Jefferson K.W., Alleyne E., O'Bannon R.E., Shirley A. Cognitive-behavioral intervention to reduce African American adolescents' risk for HIV infection. Journal of Consulting and Clinical Psychology 1995, 63(2):221-237.
70. St.Lawrence J.S., Jefferson K.W., Alleyne E., Brasfield T.L. Comparison of education versus behavioral skills training interventions in lowering sexual HIV-risk behavior of substance-dependent adolescents. Journal of Consulting and Clinical Psychology 1995, 63(1):154-157.
71. Stone P.W., Teutsch S.M., Chapman R.H., Bell C., Goldie S.J., Neumann P.J. Cost-utility analyses of clinical preventive services: Published ratios, 1976-1997. American Journal of Preventive Medicine 2000, 19:15-23.
72. Streissguth A.P., Grant T.M., Barr H.M., Brown Z.A., Martin J.C., Mayock D.E., et al. Cocaine and the use of alcohol and other drugs during pregnancy. American Journal of Obstetrics and Gynecology 1991, 164:1239-1243.
73. Svikis D.S., Golden A.S., Huggins G.R., Pickens R.W., McCaul M.E., Velez M.L., et al. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug and Alcohol Dependence 1997, 45(1-2):105-113.
74. Svikis D., McCaul M., Feng T., Stuart M., Fox M., Stokes E. Drug dependence during pregnancy. Effect of an on-site support group. The Journal of Reproductive Medicine 1998, 43(9):799-805.
75. Sweat M.D., O'Reilly K.R., Schmid G.P., Denison J., de Zoysa I. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. AIDS 2004, 18(12):1661-1671.
76. Tao G., Remafedi G. Economic evaluation of an HIV prevention intervention for gay and bisexual male adolescents. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998, 17:83-90.
77. Teerawattananon Y., Vos T., Tangcharoensathien V., Mugford M. Cost-effectiveness of models for prevention of vertical HIV transmission - Voluntary counseling and testing and choices of drug regimen. Cost Effectiveness and Resource Allocation 2005, 3:7.
78. The Foundation for AIDS Research (amfAR) Young People and HIV/AIDS November. Available. http://www.amfar.org/abouthiv/article.aspx?id=3596.
79. United Kingdom National Health Service Centre for Reviews and Dissemination Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report 4 2001, University of York, York, March. Available. http://www.medepi.net/meta/guidelines/Overview_CRD_Guidelines.pdf, 2nd ed.
80. Weinstein M. Can cost-effective health care = better health care?. Harvard Public Health Review Winter 2010, Available. http://www.hsph.harvard.edu/news/hphr/winter-2010/winter10assessment.html.
81. Wilkinson D., Floyd K., Gilks C.F. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa. South African Medical Journal 2000, 90(8):794-798.